Clascoterone - Cassiopea SpA

Drug Profile

Clascoterone - Cassiopea SpA

Alternative Names: Breezula; CB-03-01; Cortexolone 17alpha-propionate; Winlevi

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cassiopea; Cosmo Pharmaceuticals; Intrepid Therapeutics
  • Class Antiacnes; Esters; Pregnenediones; Propionates; Skin disorder therapies; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Alopecia

Most Recent Events

  • 16 Jul 2018 Interim efficacy and adverse events data from a phase II trial in Alopecia released by Cassiopea
  • 16 Jul 2018 Cassiopea plans a phase II trial for Alopecia (In adults) in female patients
  • 16 Jul 2018 Cassiopea plans a phase III trial for Alopecia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top